Skip to main content
Sunshine Lake Pharma Co., Ltd. logo

Sunshine Lake Pharma Co., Ltd. — Investor Relations & Filings

Ticker · 6887 ISIN · CNE1000070M8 HKEX Manufacturing
Open in API
Filings indexed 85 across all filing types
Latest filing 2026-03-31 Earnings Release
Country HK Hong Kong
Listing HKEX 6887

About Sunshine Lake Pharma Co., Ltd.

https://www.hecpharm.com

Sunshine Lake Pharma Co., Ltd. is a research-based, vertically integrated pharmaceutical company engaged in the R&D, production, and commercialization of innovative pharmaceutical products. Its core therapeutic focus areas include infectious diseases, chronic diseases, and oncology, with pipeline assets also targeting conditions such as psoriasis and rheumatoid arthritis. The company emphasizes the globalization and accelerated commercialization of its innovative drug portfolio. To enhance its R&D capabilities, Sunshine Lake Pharma utilizes advanced technology platforms, notably through strategic investments in joint ventures focused on AI and robotics for drug discovery. It also participates in the sourcing and supply of pharmaceutical and animal health ingredients.

Recent filings

Filing Released Lang Actions
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025
Earnings Release Classification · 95% confidence The document is an announcement titled “ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2025,” published on the Hong Kong Exchange. It provides key financial highlights (revenue, profit, EPS), dividend decision, and a Management Discussion & Analysis section summarizing industry review, company overview, and pipeline updates. It is not the full statutory Annual Report (10-K) but the initial public release of the year‐end results. Therefore, it is classified as an Earnings Release. FY 2025
2026-03-31 English
NOTICE OF BOARD MEETING
Report Publication Announcement Classification · 100% confidence The document is a 'Notice of Board Meeting' issued by Sunshine Lake Pharma Co., Ltd. It announces the date of a future board meeting to approve annual results and consider dividends. It does not contain the actual financial results or the report itself, but rather serves as an announcement regarding the upcoming publication of the annual report. According to the 'Menu vs Meal' rule, an announcement regarding the timing or release of a report is classified as a Report Publication Announcement (RPA).
2026-03-19 English
POSITIVE PROFIT ALERT
Earnings Release Classification · 100% confidence The document is a 'Positive Profit Alert' issued by Sunshine Lake Pharma Co., Ltd. It provides a preliminary estimate of financial performance (net profit) for the year ended 31 December 2025, ahead of the full annual results. This type of announcement, which provides key financial highlights and expectations before the formal report, is classified as an Earnings Release (ER). FY 2025
2026-03-13 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2026
Regulatory Filings Classification · 95% confidence The document is a 'Monthly Return for Equity Issuer' (Form FF301) filed with the Hong Kong Stock Exchange (HKEX). This form is a standard regulatory requirement for listed companies in Hong Kong to report monthly movements in securities, share capital, and treasury shares. As it is a recurring regulatory filing regarding share capital and securities movements that does not fit into specific categories like 'Share Issue' (which usually refers to a specific event) or 'Transaction in Own Shares' (which is a specific activity), it is best classified as a general regulatory filing.
2026-03-03 English
VOLUNTARY ANNOUNCEMENT THE ACCEPTANCE BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION OF INVESTIGATIONAL NEW DRUG APPLICATION FOR HEC-648 INJECTION, A MONOCLONAL ANTIBODY TARGETING THE G PROTEIN OF
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement from Sunshine Lake Pharma Co., Ltd. regarding the acceptance of an Investigational New Drug (IND) application by the China National Medical Products Administration. It describes the drug's development, clinical trial status, and strategic significance. As this is a regulatory announcement regarding company operations and product development that does not fit into specific categories like financial reports, dividends, or board changes, it is classified as a general regulatory filing.
2026-02-24 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2026
Transaction in Own Shares Classification · 100% confidence The document is a 'Monthly Return for Equity Issuer' filed with the Hong Kong Exchanges and Clearing Limited. It details movements in securities, specifically changes in issued shares and treasury shares (share buybacks). According to the filing definitions, a report detailing the company buying back or selling its own shares is classified as 'Transaction in Own Shares' (POS).
2026-02-03 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.